Results 31 to 40 of about 9,643,208 (350)
Two-year trajectory of fall risk in people with Parkinson disease: a latent class analysis [PDF]
, 2016 Published in final edited form as: Arch Phys Med Rehabil. 2016 March ; 97(3): 372–379.e1. doi:10.1016/j.apmr.2015.10.105.OBJECTIVE: To examine fall risk trajectories occurring naturally in a sample of individuals with early to middle stage Parkinson ...
Cavanaugh, James T. +8 more
core +1 more source
Microglia in Parkinson’s Disease
Journal of Parkinson's Disease, 2022 Microglia are the primary resident immune cells of the central nervous system. Neuropathological reports have identified augmented microglial activation in brains of patients with neurodegenerative disorders including Parkinson’s disease (PD).
N. Stefanova
semanticscholar +1 more source
Parkinson's Disease, 2015 Balance dysfunction (BD) in Parkinson’s disease (PD) is a disabling symptom, difficult to treat and predisposing to falls. The dopaminergic drugs or deep brain stimulation does not always provide significant improvements of BD and rehabilitative ...
Davide Ferrazzoli +7 more
doaj +1 more source
How to spot ocular abnormalities in progressive supranuclear palsy? A practical review
Translational Neurodegeneration, 2019 Background For parkinsonian disorders, progressive supranuclear palsy (PSP) continues to be significant for differential diagnosis. PSP presents a range of ocular abnormalities that have been suggested as optional tools for its early detection, apart ...
Onanong Phokaewvarangkul +1 more
doaj +1 more source
JAMA Neurology, 2020 Key Points Question Does ambroxol cross the blood-brain barrier, and what are the biochemical changes associated with ambroxol therapy in patients with Parkinson disease with and without glucocerebrosidase gene mutations?
S. Mullin +20 more
semanticscholar +1 more source
Reversing Parkinson Disease Model with in situ Converted Nigral Neurons
Nature, 2020 Parkinson’s disease is characterized by loss of dopamine neurons in the substantia nigra1. Similar to other major neurodegenerative disorders, there are no disease-modifying treatments for Parkinson’s disease.
Hao Qian +14 more
semanticscholar +1 more source
Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease
Frontiers in Cell and Developmental Biology, 2020 Parkinson disease, the second most common movement disorder, is a complex neurodegenerative disorder hallmarked by the accumulation of alpha-synuclein, a neural-specific small protein associated with neuronal synapses. Mutations in the glucocerebrosidase
Tae-Un Han, Richard Sam, Ellen Sidransky
doaj +1 more source
Risk of Parkinson Disease and Secondary Parkinsonism in Myocardial Infarction Survivors
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background In addition to primary neurodegenerative processes, vascular disorders, such as stroke, can lead to parkinsonism. However, some cardiovascular risk factors, such as smoking and elevated cholesterol levels, are associated with reduced risk of ...
Jens Sundbøll +7 more
doaj +1 more source
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. [PDF]
, 2019 The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid into plaques and hyperphosphorylated tau into tangles.
Brundin, P +26 more
core +3 more sources
Highly challenging balance program reduces fall rate in Parkinson disease [PDF]
, 2016 Published in final edited form as: J Neurol Phys Ther. 2016 January ; 40(1): 24–30. doi:10.1097/NPT.0000000000000111BACKGROUND AND PURPOSE: There is a paucity of effective treatment options to reduce falls in Parkinson disease (PD).
DeAngelis, Tamara R. +5 more
core +1 more source